NCT01979276 · OUTCOME

Time to Disease Progression (Progression Free Survival)

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma · Source last updated 2018-06-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: cycles (defined as 28 days)
Interval / dispersion: Full Range
Time frame: From start of treatment, to date of disease progression (on average, ten 28-day cycles)

Groups in this outcome

ALL Patients

Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
ALL Patients	2

Reported measurements

Source class 1

Values in cycles (defined as 28 days) · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
ALL Patients	9.5	Not reported	1	18	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1
upper Limit
18
value
9.5

denoms

counts
group Id
OG000
value
2
units
Participants

dispersion Type

Full Range

groups

description
Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined
id
OG000
title
ALL Patients

param Type

MEAN

reporting Status

POSTED

time Frame

From start of treatment, to date of disease progression (on average, ten 28-day cycles)

title

Time to Disease Progression (Progression Free Survival)

type

SECONDARY

unit Of Measure

cycles (defined as 28 days)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice